However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value.
Some of the views expressed in the following notes on newly approved products should be regarded as preliminary, as there may have been limited published data at the time of publication, and little experience in Australia of their safety or efficacy.
